Multiple Myeloma: Bone Pain, Anemia, and Modern Treatment

Multiple myeloma is a cancer of plasma cells, a type of white blood cell that normally helps the body fight infection. It can affect the bones, blood counts, kidneys and immune system, but modern treatments have greatly expanded the options for controlling the disease and improving quality of life.

Overview

Multiple myeloma is a blood cancer that begins in plasma cells. Plasma cells are made in the bone marrow and normally produce antibodies, which help protect the body from infection. In multiple myeloma, a group of abnormal plasma cells multiplies and can crowd out healthy blood-forming cells. These myeloma cells often produce an abnormal antibody or antibody fragment called monoclonal protein, M protein or light chains.

The condition can affect several body systems. It may weaken bones, lower red blood cell counts, interfere with kidney function and reduce the body’s ability to fight infections. Doctors often look for features sometimes summarized as CRAB: high calcium, renal or kidney impairment, anemia and bone disease. Not every patient has all of these findings, and some people are diagnosed before major symptoms develop.

Multiple myeloma is different from monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma. MGUS and smoldering myeloma are plasma cell conditions that may be monitored closely because they can progress in some people. Active multiple myeloma requires treatment when there is organ damage or specific high-risk features that show the disease is likely to cause harm.

Symptoms

Symptoms of multiple myeloma can be subtle at first and may be mistaken for common problems such as back strain, fatigue or age-related aches. Bone pain is one of the most recognized symptoms. It often affects the back, ribs, hips or skull and may be persistent rather than related to a single injury. Weakened bones can sometimes lead to fractures after minor trauma or even during normal activity.

Anemia is also common because myeloma cells can reduce the marrow’s ability to make healthy red blood cells. This may cause tiredness, shortness of breath with activity, dizziness, pale skin or reduced exercise tolerance. Some people develop frequent or unusually severe infections because normal antibody production is impaired.

Other symptoms can occur when myeloma affects calcium levels or kidney function. High calcium may cause thirst, constipation, nausea, confusion or increased urination. Kidney problems may cause swelling, reduced urine output, abnormal blood test results or no obvious symptoms until tests are performed.

• Persistent back, rib, hip or shoulder pain
• Unexplained fatigue or weakness
• Repeated infections or slow recovery from infections
• Numbness, tingling or weakness if nerves are affected
• Unexplained weight loss or reduced appetite

Causes & Risk Factors

The exact cause of multiple myeloma is not fully understood. It develops when genetic changes occur inside a plasma cell, allowing it to grow and survive longer than it should. These changes are not usually inherited in a simple way, and most people with multiple myeloma do not have a clear family pattern. Researchers continue to study why some plasma cell conditions remain stable while others progress to active disease.

Several factors are associated with a higher risk. Multiple myeloma is more common with increasing age and is rarely diagnosed in younger adults. It is also seen more often in men than in women. A personal history of MGUS or smoldering myeloma increases the need for regular monitoring because these conditions can sometimes progress.

Other possible risk factors include a family history of plasma cell disorders and certain environmental or occupational exposures, although these links are not always straightforward. Having a risk factor does not mean a person will develop multiple myeloma, and many patients have no identifiable risk factor beyond age. The most important step is appropriate evaluation when symptoms or abnormal laboratory results suggest a plasma cell disorder.

Diagnosis

Diagnosis begins with a medical history, physical examination and laboratory testing. Blood tests may include a complete blood count to check for anemia, kidney function tests, calcium levels and total protein. Specialized tests look for monoclonal protein, including serum protein electrophoresis, immunofixation and serum free light chain testing. Urine testing may detect light chains that are filtered by the kidneys.

A bone marrow biopsy is usually needed to confirm the diagnosis and measure how many plasma cells are present. The sample can also be studied with genetic and chromosome tests, such as fluorescence in situ hybridization, to identify risk features that may influence treatment planning. These results help the care team understand the biology of the disease rather than relying on symptoms alone.

Imaging is important because standard X-rays may miss early bone changes. Depending on the situation, doctors may use low-dose whole-body CT, MRI or PET-CT to look for bone lesions, fractures, spinal cord pressure or areas of active disease. Diagnosis and staging combine symptoms, organ involvement, laboratory values, imaging findings and risk markers. This comprehensive approach helps guide whether immediate treatment is needed and which treatment plan is most suitable.

Treatment Options

Treatment for multiple myeloma is individualized. Factors include age, general health, kidney function, symptoms, genetic risk features, prior treatments and whether a patient is eligible for autologous stem cell transplant. Modern care often uses combinations of medicines that work in different ways, such as proteasome inhibitors, immunomodulatory drugs, corticosteroids and monoclonal antibodies. These combinations aim to reduce myeloma cells quickly while maintaining safety and quality of life.

For eligible patients, autologous stem cell transplant may be part of initial therapy. In this procedure, a patient’s own blood-forming stem cells are collected, high-dose therapy is given to reduce the myeloma burden and the stored stem cells are returned to help restore marrow function. Transplant is not the right choice for everyone, and some patients receive highly effective non-transplant regimens instead. Many people also receive maintenance therapy after initial treatment to help keep the disease controlled.

Relapsed or refractory myeloma means the disease has returned or is no longer responding adequately to treatment. Options have expanded to include newer targeted combinations, antibody-based treatments, bispecific antibodies and, for selected patients, CAR T-cell therapy. The choice depends on previous medicines, response duration, side effects and patient goals. Clinical trials may also be discussed when appropriate.

Supportive care is a central part of treatment. It may include medicines to strengthen bones, pain control, treatment of anemia, infection prevention, vaccines, hydration guidance, kidney-protective measures, radiation therapy for painful bone lesions and orthopedic or spine procedures when fractures or instability occur. Supportive care is not secondary; it helps reduce complications and allows patients to tolerate cancer treatment more safely.

Prevention & Self-care

There is no proven way to prevent most cases of multiple myeloma. Because the disease often develops from internal changes in plasma cells, general lifestyle measures cannot eliminate the risk. However, people with MGUS or smoldering myeloma can benefit from regular follow-up so that progression is recognized early. Monitoring schedules should be personalized by a hematologist.

Self-care during and after treatment focuses on protecting bones, kidneys and the immune system. Patients are usually encouraged to stay well hydrated unless a doctor advises fluid restriction, avoid non-prescribed medicines that can stress the kidneys, report infection symptoms promptly and maintain safe physical activity. A physiotherapist or rehabilitation specialist can help choose exercises that support strength and balance while reducing fracture risk.

Nutrition should be practical and sustainable. A balanced diet with adequate protein, fruits, vegetables and calcium or vitamin D guidance from the care team may support overall health, but supplements should not be started without medical advice. Patients should also discuss dental health before bone-strengthening medicines, because some treatments require dental precautions. Emotional support, sleep routines and clear communication with the care team can make long-term management easier.

When to See a Doctor

A person should seek medical evaluation for persistent or worsening bone pain, especially in the back, ribs or hips, or for a fracture that occurs after a minor injury. Unexplained fatigue, shortness of breath, repeated infections, high calcium results, kidney function changes or abnormal protein levels on blood tests also deserve prompt review. These symptoms do not always mean cancer, but they should not be ignored.

Urgent assessment is important if back pain is accompanied by leg weakness, numbness, loss of bladder or bowel control, confusion, severe dehydration symptoms or markedly reduced urination. These situations may reflect complications that need rapid treatment. Early intervention can help protect nerves, kidneys and bones.

People diagnosed with multiple myeloma should be cared for by a multidisciplinary team, typically including hematology, oncology, radiology, pathology, nephrology, orthopedics, radiation oncology, pain management and supportive care professionals. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat multiple myeloma for international patients, with care plans based on each patient’s medical needs. Patients should always discuss individual risks, benefits and alternatives with a qualified doctor.

Frequently asked questions

Is multiple myeloma the same as bone cancer?

Multiple myeloma is not a primary bone cancer. It is a blood cancer of plasma cells that live in the bone marrow, but it often causes bone damage and bone pain. This is why imaging and bone-protective treatment are important parts of care.

Why does multiple myeloma cause anemia?

Myeloma cells can crowd the bone marrow and reduce its ability to make normal red blood cells. Anemia may also be influenced by kidney problems, inflammation or treatment effects. Doctors monitor blood counts regularly and treat anemia according to its cause and severity.

Can multiple myeloma be treated without a stem cell transplant?

Yes. Many patients receive effective treatment combinations without a stem cell transplant, especially if transplant is not suitable because of age, health conditions or personal preference. For eligible patients, transplant may still be considered as part of a broader treatment plan.

What does remission mean in multiple myeloma?

Remission means the disease has responded to treatment and signs of myeloma have decreased significantly. The depth of response can vary, from partial response to very deep responses measured with sensitive tests. Ongoing monitoring is still needed because myeloma can return.

How is bone pain from multiple myeloma managed?

Management may include myeloma-directed treatment, pain medicines, bone-strengthening medicines, radiation therapy for selected painful areas and procedures to stabilize fractures when needed. Physical activity plans should be tailored to bone strength and fracture risk. Patients should report new or worsening pain promptly.

Are infections more common in multiple myeloma?

Yes, infections can be more common because myeloma affects normal antibody production and some treatments temporarily weaken immunity. Vaccination, early reporting of fever or infection symptoms and individualized preventive medicines may be recommended. Patients should follow their care team’s infection-prevention advice.

References

• International Myeloma Foundation
• American Society of Hematology
• National Cancer Institute
• European Society for Medical Oncology
• International Myeloma Working Group

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.